FDA Approves Lilly's Evista

Evista affects the cycle of bone formation and breakdown in the body, and reduces loss of bone tissue.

Evista is used to treat or prevent osteoporosis in postmenopausal women. It is also used to reduce the risk of invasive breast cancer in postmenopausal women who have osteoporosis or who are at risk of invasive breast cancer.

Raloxifene is used to prevent and treat bone loss (osteoporosis) in women after menopause. Maintaining strong bones by slowing bone loss helps to reduce the risk of fractures.
Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive) in women after menopause.
This drug is different from hormones (including estrogens and progestins). It works by acting like estrogen (as a selective estrogen receptor modulator or SERM) in some parts of the body. Raloxifene helps to preserve bone mass, but it does not affect the breast and uterus like estrogen or relieve symptoms of menopause such as hot flashes.
This medication is not recommended for use in women before menopause. It should not be used in children.
This medication should not be used to prevent heart disease.

Drug type: Evista is a hormone therapy. This medication is classified as an Selective Estrogen Receptor Modulator (SERM). (For more detail, see "How this drug works" section below).

What this drug is used for:

This medicine is given to prevent or treat osteoporosis (bone thinning) in women who have stopped having their periods (postmenopausal).
Raloxifen has been approved for reduction in risk of breast cancer in postmenopausal women who have osteoporosis and for postmenopausal women at high risk for breast cancer.

Evista (raloxifene hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (agonism) and and the blockade of estrogenic pathways in other tissues (antagonism).
Evista is specifically approved for the treatment and prevention of osteoporosis in postmenopausal women, the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. Evista is supplied as a 60 mg tablet designed for oral administration. The recommended initial dose of the drug is one 60 mg tablet daily, which may be administered any time of day without regard to meals.